Bridgewater Associates LP Sells 9,138 Shares of Amedisys, Inc. (NASDAQ:AMED)

Bridgewater Associates LP decreased its holdings in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 71.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,686 shares of the health services provider's stock after selling 9,138 shares during the quarter. Bridgewater Associates LP's holdings in Amedisys were worth $335,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. increased its position in Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after purchasing an additional 124 shares during the last quarter. HBW Advisory Services LLC acquired a new position in Amedisys during the 4th quarter valued at $38,000. Versant Capital Management Inc grew its position in Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock worth $41,000 after buying an additional 183 shares in the last quarter. Vestcor Inc bought a new stake in shares of Amedisys during the fourth quarter valued at approximately $73,000. Finally, Venturi Wealth Management LLC lifted its holdings in shares of Amedisys by 397.4% during the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock worth $89,000 after acquiring an additional 779 shares during the period. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Stock Up 0.2 %

Amedisys stock traded up $0.15 during midday trading on Friday, reaching $94.42. The stock had a trading volume of 168,666 shares, compared to its average volume of 404,143. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95. The company has a fifty day moving average price of $92.17 and a two-hundred day moving average price of $91.83. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $3.10 billion, a P/E ratio of 37.47, a PEG ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The company had revenue of $594.78 million for the quarter, compared to analysts' expectations of $597.43 million. As a group, equities analysts expect that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Stephens reiterated an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada restated an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $100.75.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.